Dr. Prakash is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3550 NE Loop 286
Paris, TX 75460Phone+1 903-785-0031Fax+1 903-784-6755
Summary
- Dr Sucharu Prakash is the Medical Director and an Oncology/ Hematology specialist at Texas Oncology Paris. He is a fierce advocate for improving the healthcare of all Texans, especially in rural communities of Texas and across America. He is a member of the ASCO Task Force for rural cancer care and has spoken on this matter at various forums. He is the President-Elect of Texas Society of Clinical Oncology, is on the Board of Directors of Texas Oncology, and a member of the TMA’s Committee on Cancer. Through these associations, he strives to influence health policy with the goal of improving cancer care and lives of Texans and all Americans. As a Principal Investigator for US Oncology Research, he has brought numerous clinical trials to the patients of Lamar County and surrounding areas. He is a columnist for local news outlets contributing regular health care articles. He and his wife are active philanthropists in their community.
Education & Training
- Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
- Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2000
- Bon Secours HospitalResidency, Internal Medicine, 1994 - 1997
- Dayanand Medical College Class of 1991
Certifications & Licensure
- TX State Medical License 2000 - 2025
- MI State Medical License 1996 - 2003
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
- Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) Start of enrollment: 2021 Jun 02
- Join now to see all
Press Mentions
- Closing the Care Gap for Rural PopulationsFebruary 3rd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: